Protara Therapeutics, Inc. (TARA)
Nasdaq: TARA · Biological Products, (No Diagnostic Substances) · New York, NY · filing with the SEC since 2006
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
| Report filed | Mar 10, 2026 | Mar 5, 2025 | Mar 13, 2024 | Mar 8, 2023 | Mar 9, 2022 | Mar 11, 2021 | Mar 20, 2020 | Mar 13, 2019 | Mar 14, 2018 | Mar 16, 2017 |
| For lenders | ||||||||||
| Net interest income | · | · | · | · | · | -34r | · | · | · | · |
| For insurers | ||||||||||
| Net investment income | · | · | · | 17 | · | · | · | · | · | · |
| Research and development | 42,633 | 31,704 | 24,989 | 16,808 | 21,088 | 11,982 | 3,878r | 11,848 | 21,686 | 18,869 |
| General and administrative | 21,916 | 17,450 | 18,624 | 20,737 | 26,401 | 22,462 | 3,952r | 9,524 | 8,676 | 9,836 |
| Total operating expenses | 64,549 | 49,154 | 43,613 | 67,062 | 47,489 | 34,444 | 7,830r | 21,372 | 30,362 | 28,705 |
| Operating income | -64,549 | -49,154 | -43,613 | -67,062 | -47,489 | -34,444 | -7,830r | -21,372 | -30,362 | -28,705 |
| Interest expense | · | · | · | · | 0 | 34 | · | · | · | · |
| Interest and investment income | 6,380 | 4,171 | 3,193 | 1,110 | 237 | 500 | 262 | 436 | 259 | 193 |
| Other income (expense), net | · | · | · | · | · | · | · | 207 | 139 | -14 |
| Total non-operating income (expense) | 7,110 | 4,558 | 3,193 | 1,110 | 237 | 466 | 262 | 643 | 398 | 179 |
| Income before income taxes | 57,351 | 44,563 | · | · | · | · | -14,992 | -20,729 | -29,964 | -28,526 |
| Net income including non-controlling interests | · | · | · | · | -47,252 | -33,978 | -7,830 | · | · | · |
| Net income | -57,439 | -44,596 | -40,420 | -65,952 | -47,252 | -33,978 | -7,830r | -20,729 | -29,964 | -28,526 |
| Net income to common shareholders | · | · | -40,420 | -65,952r | 47,252 | 33,978 | · | -20,729 | -36,711 | -28,526 |
| Earnings per share, basic | -1.34 | -2.17 | -3.57 | -5.86 | -4.21 | · | · | · | · | · |
| Earnings per share, diluted | -1.34 | -2.17 | -3.57 | -5.86 | -4.21 | · | · | · | · | · |
| Earnings per share, basic and diluted | · | · | · | · | -4.21 | -4.70 | -3.04r | -45.80r | -2.13 | -1.72 |
| Weighted average shares, basic | 42,836,129 | 20,592,847 | 11,331,338 | 11,259,615 | · | · | · | · | · | · |
| Weighted average shares, diluted | 42,836,129 | 20,592,847 | 11,331,338 | 11,259,615 | 11,232,576 | · | · | · | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | 11,232,576 | 7,233,913 | 2,577,493r | 452,555r | 17,274,326 | 16,561,799 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Net interest income interest earned less interest paid
us-gaap:InterestIncomeExpenseNetNet investment income what its investments earned
us-gaap:NetInvestmentIncomeResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterest
us-gaap:InvestmentIncomeNetOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted